Imbruvica faces challenges on multiple fronts.

Raludotatug deruxtecan, ABBV-383 and zongertinib advance into phase 3, while other pivotal programmes are expanded.

Buoyed by the success of cadonilimab and ivonescimab the Chinese group takes two more bispecific MAbs into human trials.

Competitors struggle, while MorphoSys investors see a path forward for pelabresib after all.

Rates of infection-related deaths continue to raise eyebrows, but the company has some potential explanations.

Jaypirca secures a CLL label, though plans to dominate will be tempered by this market’s fast-changing nature.

Yet another ADC deal sees AbbVie buy ImmunoGen, ending a 40-year rollercoaster ride with a 100% overnight premium.